2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Thursday, May 18, 2017

5:30PM-7:00PM: Abstract Number: 138

Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis

Genetics and Pathogenesis Poster Session

5:30PM-7:00PM: Abstract Number: 140

Modular Gene Expression Discrimination of Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Subphenotypes in Peripheral Blood

Genetics and Pathogenesis Poster Session

5:30PM-7:00PM: Abstract Number: 92

Mycophenolate Mofetil is an Effective Induction Therapy Agent in Childhood-onset Pure Membranous Lupus Nephritis

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 142

Neutrophils and monocytes in the early inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis

Genetics and Pathogenesis Poster Session

5:30PM-7:00PM: Abstract Number: 62

Novel Approach to Quantifying Joint Pathology Via Musculoskeletal Ultrasound in Newly Diagnosed Juvenile Idiopathic Arthritis

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 148

Oral Microbial Profile in Juvenile Idiopathic Arthritis

Genetics and Pathogenesis Poster Session

5:30PM-7:00PM: Abstract Number: 118

Oxygen Saturation Recordings in Pediatric Rheumatology Patients At Risk For Lung Disease

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 60

Paediatric Arthritis Rehabilitation Exercise Study

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 49

Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 63

Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 91

Peri-pubertal Onset of Systemic Lupus Erythematosus is Associated with Shorter than Expected Adult Height

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 99

PILOT STUDY MEASURING HEPCIDIN AND ARTERIAL STIFFNESS IN CHILDREN WITH SLE AND LUPUS NEPHRITIS

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 79

Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 84

Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis

Clinical and Therapeutic Poster Session

5:30PM-7:00PM: Abstract Number: 78

Predictors of Outcome Following Tonsillectomy in Periodic Fever, Aphthous Stomatitis Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome

Clinical and Therapeutic Poster Session

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].